Labiana Health (STU:8RK) ROCE %: 12.95% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:8RK Labiana Health SA STU:8RK
65 GF Score
Price €6.60
GF Value €3.25
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Labiana Health ROCE %?

Labiana Health STU:8RK +1.54% 65 ROCE % is 12.95% as of Dec. 2025. GuruFocus rates STU:8RK with a GF Score™ of 65/100 and a GF Value™ of €3.25 (Significantly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Labiana Health's annualized ROCE % for the quarter that ended in Dec. 2025 was 12.95%.

Labiana Health  (STU:8RK) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Labiana Health ROCE % Related Terms

Labiana Health ROCE % Historical Data

* Premium members only.

The historical data trend for Labiana Health's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Labiana Health ROCE % Chart

Labiana Health Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial 0.01 -18.02 -6.57 14.97 21.95

Labiana Health Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.05 24.92 5.67 31.77 12.95
STU:8RK
65GF Score
Labiana Health SA STU:8RK
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Labiana Health ROCE % Calculation

Labiana Health's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=7.105/( ( (52.002 - 22.159) + (57.543 - 22.662) )/ 2 )
=7.105/( (29.843+34.881)/ 2 )
=7.105/32.362
=21.95 %

Labiana Health's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=4.346/( ( (54.377 - 22.123) + (57.543 - 22.662) )/ 2 )
=4.346/( ( 32.254 + 34.881 )/ 2 )
=4.346/33.5675
=12.95 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 12.95% mean?
Labiana Health (STU:8RK) has a ROCE % of 12.95% as of Dec. 2025.
Is Labiana Health's ROCE % too high?
Labiana Health's current ROCE % is 12.95%. The Drug Manufacturers industry median ROCE % is 7.04. Labiana Health's value of 12.95% is 83.9% above this industry median. Overall, Labiana Health has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labiana Health's ROCE % compare to ZTS and UTHR?
Labiana Health's ROCE % of 12.95% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.04. Labiana Health's value of 12.95% is 83.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labiana Health's current ROCE % of 12.95% is 83.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labiana Health's current ROCE % is 12.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labiana Health stock overvalued right now?
Based on GuruFocus' analysis, Labiana Health (STU:8RK) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.25, compared to a current price of €6.60 — trading 103.1% above its estimated fair value. The current ROCE % is 12.95% and 83.9% above the Drug Manufacturers industry median of 7.04. Labiana Health's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Labiana Health (STU:8RK), the current ROCE % is 12.95% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Labiana Health (STU:8RK) Overvalued in 2026?

Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued. The current stock price of €6.60 is trading 103.1% above its estimated GF Value™ of €3.25. GuruFocus considers Labiana Health to be Significantly Overvalued.

Key valuation signals for STU:8RK:

  • ROCE %: 12.95%
  • GF Value™: €3.25 vs. price of €6.60 (103.1% above fair value)
  • GF Score™: 65/100 with 4 warning signs
  • Industry Position: 83.9% above the Drug Manufacturers median

No single metric tells the full story. See the STU:8RK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Labiana Health Business Description

Other Exchanges LAB:Spain8RK:Germany
Address Avenida Europa, 34 1st D, Pozuelo de Alarcon, Madrid, ESP, 28023
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
65GF Score

Get the complete analysis for STU:8RK

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.60
Price
€3.25
GF Value